Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/000331976902000206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19.
Clin Appl Thromb Hemost
November 2024
Division of Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Tottori, Japan.
Introduction: Thrombosis is a major complication of COVID-19. D-dimer (DD) is an important coagulation fibrinolysis marker in COVID-19 and has been extensively studied. However, very little is known about the role of other fibrinolysis markers, plasmin-plasmin inhibitor complex (PIC), and fibrin monomer complex (FMC) in COVID-19.
View Article and Find Full Text PDFOPTICAL COHERENCE TOMOGRAPHY FEATURES ASSOCIATED WITH VITREOMACULAR TRACTION RELEASE AND MACULAR HOLE SIZE PROGRESSION FOLLOWING TREATMENT WITH OCRIPLASMIN.
Retina
November 2024
Technical University of Munich (TUM), Department of Ophthalmology, Hospital rechts der Isar, Munich, Germany.
Purpose: To evaluate OCT features for vitreomacular traction (VMT) release and change in macular hole (MH) size after treatment with ocriplasmin.
Methods: Patients who had undergone treatment with ocriplasmin for VMT with or without MH ≤400 µm were included. The main outcomes were VMT release and changes in minimum linear diameter MH size at 4 weeks in MHs that persisted.
[Current treatment strategies for vitreomacular traction and macular holes: a survey of retinal specialists in Germany].
Ophthalmologie
December 2024
Klinik für Augenheilkunde, Universitätsklinikum Ulm, Prittwitzstr. 43, 89075, Ulm, Deutschland.
Article Synopsis
- The study evaluates treatment strategies for vitreomacular traction (VMT) and macular holes (MF) by gathering insights from experienced retinal specialists.
- An online survey was conducted among members of the German Retina Society to assess their views, leading to data that aligns with recent S1 guidelines.
- The findings emphasize a shift toward watchful waiting for focal VMT without MF, while confirming the established efficacy and risk assessment for vitrectomy as a treatment option.
Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms.
J Thromb Haemost
November 2024
Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France; Département de Neurologie, AP-HP, Hôpital Lariboisière, FHU NeuroVasc, Paris, France.
Background: Myeloproliferative neoplasms (MPNs) are characterized by a high rate of thrombotic complications that contribute to morbidity and mortality. MPN-related thrombogenesis is assumed to be multifactorial, involving both procoagulant and proinflammatory processes. Whether impaired fibrinolysis also participates in the prothrombotic phenotype of MPN has been poorly investigated.
View Article and Find Full Text PDFPlasmin generation analysis in patients with bleeding disorder of unknown cause.
Blood Adv
November 2024
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Bleeding disorder of unknown cause (BDUC) is diagnosed after ruling out other causes, and this study analyzed data from 375 BDUC patients compared to 100 healthy controls.
- The findings revealed that BDUC patients had lower peak plasmin levels and clot density, indicating potential issues with clot structure, while still showing a higher potential for plasmin generation.
- A model including fibrinogen and plasmin generation parameters effectively distinguished BDUC patients from healthy controls, demonstrating the potential for predictive diagnostics in bleeding disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!